XNAS
WALDW
Market cap257mUSD
Jun 10, Last price
0.06USD
1D
-23.08%
1Q
-61.85%
IPO
-91.87%
Name
Waldencast PLC
Chart & Performance
P/E
—
P/S
0.02
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
274m
+25.55%
Net income
-42m
L-52.83%
CFO
-9m
L-70.38%
Profile
Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||||
Revenues | 273,868 25.55% | 218,138 31.30% | 166,133 16.61% | ||
Cost of revenue | 82,124 | 79,756 | 131,099 | ||
Unusual Expense (Income) | |||||
NOPBT | 191,744 | 138,382 | 35,034 | ||
NOPBT Margin | 70.01% | 63.44% | 21.09% | ||
Operating Taxes | 110 | (6,975) | (5,690) | ||
Tax Rate | 0.06% | ||||
NOPAT | 191,634 | 145,357 | 40,724 | ||
Net income | (42,443) -52.83% | (89,981) -22.85% | (116,624) 495.75% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 70,000 | ||||
BB yield | -6.32% | ||||
| Debt | |||||
Debt current | 32,245 | 10,929 | 22,136 | ||
Long-term debt | 165,351 | 184,726 | 197,034 | ||
Deferred revenue | |||||
Other long-term liabilities | 5,126 | 28,699 | 18,311 | ||
Net debt | 182,794 | 173,079 | 210,477 | ||
| Cash flow | |||||
Cash from operating activities | (8,820) | (29,775) | (85,014) | ||
CAPEX | (3,012) | (2,046) | (2,496) | ||
Cash from investing activities | (2,920) | (1,994) | (545,276) | ||
Cash from financing activities | 5,582 | 44,329 | 633,348 | ||
FCF | 182,277 | 141,277 | 10,781 | ||
| Balance | |||||
Cash | 14,802 | 22,576 | 8,693 | ||
Long term investments | |||||
Excess cash | 1,109 | 11,669 | 386 | ||
Stockholders' equity | (221,323) | (102,254) | 3,860 | ||
Invested Capital | 1,138,492 | 1,077,950 | 1,006,783 | ||
ROIC | 17.29% | 13.94% | 6.64% | ||
ROCE | 20.59% | 13.96% | 3.40% | ||
| EV | |||||
Common stock shares outstanding | 110,451 | 101,229 | 107,565 | ||
Price | 4.02 -63.25% | 10.94 20.55% | 9.08 -8.79% | ||
Market cap | 444,013 -59.91% | 1,107,444 13.45% | 976,150 124.46% | ||
EV | 694,425 | 1,425,170 | 1,347,286 | ||
EBITDA | 251,759 | 198,880 | 70,206 | ||
EV/EBITDA | 2.76 | 7.17 | 19.19 | ||
Interest | 17,155 | 18,906 | 12,882 | ||
Interest/NOPBT | 8.95% | 13.66% | 36.77% | ||